BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UBT251 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of UBT251\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07785934-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:UBT251: Phase 1 readout est. (NCT07785934)
DESCRIPTION:UBT251\, phase 1\, Obesity.\nStudy: Phase I Drug-Drug Interacti
 on Study of UBT251 Injection in Participants With Overweight or Obesity\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07785934
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395687-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:UBT251: Phase 2 readout est. (NCT07395687)
DESCRIPTION:UBT251\, phase 2\, Obesity.\nStudy: A Research Study on How Wel
 l Different Doses of the Medicine UBT251 Help People Living With Overweigh
 t or Obesity\nEstimated primary completion: 14 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07395687
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710768-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:UBT251: Phase 1 readout est. (NCT07710768)
DESCRIPTION:UBT251\, phase 1\, Obesity.\nStudy: A Research Study on How UBT
 251 Affects Levels of Midazolam\, Caffeine and Warfarin in the Blood of Pa
 rticipants With Excess Body Weight\nEstimated primary completion: 7 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07710768
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710729-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:UBT251: Phase 1 readout est. (NCT07710729)
DESCRIPTION:UBT251\, phase 1\, Obesity.\nStudy: A Research Study Looking In
 to How UBT251 Works With Birth Control Tablets and Emptying of the Stomach
  in Women With Excess Body Weight Not Able to Become Pregnant\nEstimated p
 rimary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ubt251#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07710729
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145151-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270604
DTEND;VALUE=DATE:20270605
SUMMARY:UBT251: Phase 2 readout est. (NCT07145151)
DESCRIPTION:UBT251\, phase 2.\nStudy: A Study of UBT251 in Participants Wit
 h Metabolic Dysfunction-Associated Steatohepatitis (MASH)\nEstimated prima
 ry completion: 4 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ubt251#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07145151
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659574-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:UBT251: Phase 3 readout est. (NCT07659574)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate
  Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）\nEstimated pr
 imary completion: 24 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ubt251#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07659574
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648225-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:UBT251: Phase 3 readout est. (NCT07648225)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (Overweight or Obesity)\nEstimated primary completion: 29 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07648225
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668388-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:UBT251: Phase 2 readout est. (NCT07668388)
DESCRIPTION:UBT251\, phase 2\, Type 2 Diabetes.\nStudy: A Research Study Co
 mparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar 
 in People With Type 2 Diabetes\nEstimated primary completion: 4 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07668388
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653477-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:UBT251: Phase 3 readout est. (NCT07653477)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic
  Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
 \nEstimated primary completion: 29 February 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07653477
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767942-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:UBT251: Phase 3 readout est. (NCT07767942)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (OSA-NPAP)\nEstimated primary completion: September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07767942
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806851-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:UBT251: Phase 3 readout est. (NCT07806851)
DESCRIPTION:UBT251\, phase 3\, Obesity.\nStudy: UBT251 Injection Phase Ⅲ 
 Study (OSA-PAP)\nEstimated primary completion: March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07806851
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134335-199@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20300711
DTEND;VALUE=DATE:20300712
SUMMARY:UBT251: Phase 2 readout est. (NCT07134335)
DESCRIPTION:UBT251\, phase 2\, Obesity.\nStudy: UBT251 Injection Phase II C
 linical Study (CKD)\nEstimated primary completion: 11 July 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07134335
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
